Thousands in Florida who rely on the AIDS Drug Assistance Program will see their coverage cut or their medication changed, ...

Merck (MRK) announced on Wednesday that its single-tablet antiviral regimen, doravirine and islatravir for adults with HIV, was found to be non-inferior to Gilead’s (GILD) once-daily HIV pill Biktarvy ...

– Investigational Long-Acting, Twice-Yearly Treatment Regimen of Lenacapavir and Broadly Neutralizing Antibodies (bNAbs) Meets Primary Endpoint in Phase 2 Study and Gains Breakthrough Therapy ...

B/F/TAF shows lower ART switching rates and higher persistence among HIV patients, especially those with mental health or substance use disorders. Medicare claims data analysis indicates B/F/TAF has ...

On Saturday, Gilead Sciences, Inc. (NASDAQ:GILD) and Merck & Co. Inc. (NYSE:MRK) revealed new results from a Phase 2 clinical study evaluating the investigational combination of islatravir and ...

In largest head-to-head randomized clinical trial evaluating the two medicines, Dovato (DTG/3TC) met the primary endpoint, demonstrating sustained non-inferior efficacy versus Biktarvy (BIC/FTC/TAF) ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of HIV research findings at the International Congress on Drug Therapy in HIV ...

Gilead’s Q3 sales increased 7% year-over-year, including 13% year-over-year growth for Biktarvy. The Liver Disease portfolio sales increased 4% to $733 million, and Veklury sales increased 9% to $692 ...

Here are four things to know. 1. Biktarvy is a once-daily, triple-combination tablet used to treat HIV infections. 2. The drug’s wholesale price will be about $36,000 per year, which falls in line ...